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 25 
Abstract 26 
Background: Scedosporium and Pseudallescheria species are the second most common lung-27 
colonizing fungi in cystic fibrosis (CF) patients. For epidemiological reasons it is important to 28 
trace sources of infection, routes of transmission and to determine whether these fungi are 29 
transient or permanent colonizers of the respiratory tract. Molecular typing methods like 30 
multilocus sequence typing (MLST) help provide this data.  31 
Methods: Clinical isolates of the P. boydii complex (including S. apiospermum and P. boydii) 32 
from CF patients in different regions of Germany were studied using MLST. Five gene loci, 33 
ACT, CAL, RPB2, BT2 and SOD2, were analysed.  34 
Results: The S. apiospermum isolates from 34 patients were assigned to 32 sequence types 35 
(ST), and the P. boydii isolates from 14 patients to eight ST. The results revealed that patients 36 
can be colonized by individual strains for years.  37 
Conclusions: The MLST scheme developed for S. apiospermum and P. boydii is a highly 38 




In CF patients, respiratory function becomes increasingly affected by fungi during the course 43 
of the underlying disease. Aspergillus fumigatus is the mould found most frequently and is 44 
associated with allergic bronchopulmonary aspergillosis or causes invasive mycosis, 45 
especially after organ transplantation. Fungi of the Pseudallescheria/Scedosporium complex 46 
rank second among colonizing hyphomycetes (2-4). This complex includes S. apiospermum, 47 
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The percentage of the respective isolates from CF patients sent to the reference laboratory at 49 
the Robert Koch-Institute (RKI) between 1995 and 2010 was 49.4 %, 23.5 %, 9.4 %, 2.4 % 50 
and 15.3 %. S. dehoogii was not found in clinical samples at all. This complex of 51 
hyphomycetes is of special importance because of diagnostic difficulties and a higher 52 
resistance to antifungal agents compared to A. fumigatus. How patients acquire these fungi is 53 
still unclear, especially because Scedosporium species are hardly ever detected in indoor air 54 
but are commonly found in polluted water and soil (5-7). Some authors reported that CF 55 
patients can be chronically colonized by S. apiospermum (8-10). Nevertheless, the following 56 
issues are as yet unclear: (i) the clinical relevance, (ii) whether patients are colonized by one 57 
or more strains, and (iii) the effect of antimycotic treatment on the colonisation with these 58 
pathogens. For epidemiological studies it is necessary to exactly identify strains on a 59 
subspecies level. MLST has proved to give highly reproducible genotyping results that are 60 
comparable worldwide (11-14). Therefore we decided to use MLST in studying 61 
S. apiospermum and P. boydii as the most frequently isolated species in the CF context within 62 
the S. apiospermum species complex in Germany.  63 
 64 
Materials and methods 65 
Fungal isolates 66 
Clinical samples from the respiratory tract of CF patients were cultivated at CF centres from 67 
geographically diverse locations in Germany. Phenotypically distinct isolates preliminarily 68 
identified as Pseudallescheria or Scedosporium species were sent to the reference laboratory. 69 
Re-identification was performed by sequencing of the internal transcribed spacer (ITS) region 70 
of the rDNA (15). The study included all S. apiospermum and P. boydii isolates received 71 
continuously between 2009 and 2010. The number of isolates was increased by including 72 
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a total of 115. Forty-seven isolates from 14 patients were identified as P. boydii (Table 1) and 74 
68 isolates from 34 patients as S. apiospermum (Table 2). Patients were between four and 41 75 
years of age at the time of the first isolation of the fungus, as documented at the CF centre 76 
currently treating the patient; on average, females were 18.9 years old and males 21.3. There 77 
was no significant difference between patients with a homozygote and heterozygote mutation 78 
of the Cystic Fibrosis Transmembrane conductance Regulator (CFTR) gene and the mean age 79 
at the time of the first isolation of the S. apiospermum species complex. 80 
Two reference strains for P. boydii (CBS 101.22T and CBS 418.73) and three reference strains 81 
for S. apiospermum (CBS 100392, CBS 100395 and CBS 117407T) were included in the 82 
study. 83 
The isolates were stored at -70 °C in MicrobankTM tubes (Pro-Lab Diagnostics, Bromborough, 84 
U.K.). Before DNA extraction the isolates were grown on Potato Dextrose Agar (PDA) for 85 
seven days at 37 °C. 86 
DNA extraction 87 
DNA extraction and purification were performed with the FFPE Tissue LEV DNA 88 
Purification Kit designed for the Maxwell® 16 Instrument (Promega, Mannheim, Germany) 89 
with minor modification of the manufacturer’s protocol. DNA was purified directly from 90 
fungal cultures. An inoculating loop of mycelium was suspended in 300 μl of lysis buffer and 91 
incubated with shaking at 70 °C for 10 min. The final DNA extraction volume was 120 μl of 92 
bidest water. 93 
PCR amplification, sequencing and MLST analysis 94 
Adapted from earlier genotyping studies (16-24), PCR amplification with different primer 95 
pairs was attempted for five isolates from each species (S. apiospermum, P. boydii) for the 96 
following genes: actin (ACT), calmodulin (CAL, exon 3-4), second largest subunit of RNA 97 


































































 - 5 - 
(SOD2) and elongation factor 1 alpha (EF1α). To optimise the amplification of calmodulin in 99 
S. apiospermum and P. boydii isolates, one primer pair was newly designed based on 100 
sequences available from the NCBI website.  101 
The PCR assay (25 μl) included 1 μl of fungal DNA extract, 1 μM of each gene-specific 102 
primer (Table 3, TIB MOLBIOL, Berlin, Germany), 0.2 mM of each deoxynucleoside 103 
triphosphate (Roche, Mannheim, Germany), 1 x BioThermTM PCR buffer with 1.5 mM of 104 
MgCL2 (Rapidozym, Berlin, Germany) and 1.25 U BioThermTM Taq DNA polymerase 105 
(Rapidozym, Berlin, Germany). For SOD2 a Pfu DNA polymerase and 1 × Pfu buffer with 106 
2 mM of MgSO4 (Fermentas, St. Leon-Rot, Germany) were used for the PCR reaction. 107 
The amplification for all targeted genes was performed in a T1-Thermocycler (Biometra, 108 
Göttingen, Germany) as follows: 5 min of initial denaturation at 95 °C, followed by 35 cycles 109 
at 95 °C for 30 sec, gene-specific annealing temperature for 30 sec (Table 3) and 72 °C for 110 
1 min (for RPB2 the annealing time was 2.5 min). The final extension step was 7 min at 111 
72 °C. The amplification products were electrophoretically resolved on a 1.4 % agarose TBE 112 
gel (0.089 M Tris base, 0.089 M boric acid and 0.002 M EDTA) including GelRedTM (0.83 x, 113 
Biotium, Hayward, CA, USA) and visualized by UV transillumination (BioDocAnalyze, 114 
Biometra, Göttingen, Germany). The products were purified using the QIAquick PCR 115 
purification kit (Qiagen, Hilden, Germany). For the sequencing of both strands the 116 
amplification primers were used. Sequencing was performed according to the BigDye® 117 
Termination v3.1 Cycle Sequencing Kit, and the reactions were run on the ABI Prism 3130 118 
Genetic Analyzer (Applied Biosystems, Darmstadt, Germany). Sequencing analysis was 119 
performed using the SeqMan pro (Lasergene DNASTAR version 8.1.5) and the BioEdit 120 
sequence Alignment Editor (version 7.0.9.0). The sequences were trimmed; starting and 121 
endpoints are defined in Table 4. Each variable sequence was classified as a unique allele 122 
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each locus were BLAST searched against the NCBI GenBank to prove the specificity of the 124 
amplified product. 125 




More than one allele type was found for the ITS region of rDNA in both species; however, 130 
this was not included in the MLST scheme because it did not provide new information on the 131 
ST. For all isolates studied sequence data were obtained for the five MLST loci ACT, CAL, 132 
RPB2, BT2 and SOD2. Amplification or sequencing of EF1α failed with the primer pairs 133 
studied. In total, for the five gene fragments 3,375 bp were analysed. The allele types of each 134 
gene locus were clearly distinct between P. boydii and S. apiospermum. 135 
In P. boydii 128 (3.8 %) polymorphic sites were identified among the five gene loci, whereas 136 
in S. apiospermum 92 (2.7 %) variable nucleotides were found (Table 4). In P. boydii analysis 137 
of the loci ACT and RPB2 resulted in four alleles, of CAL and BT2 in five and of SOD2 in six 138 
allele types. The variability of nucleotides per locus ranged between 1.6 % (CAL) and 14.6 % 139 
(SOD2). In comparison to P. boydii, twelve alleles were observed for the SOD2 locus in 140 
S. apiospermum. For the other loci in S. apiospermum four to eight alleles were identified. 141 
The lowest variability of nucleotides was noted in CAL and ACT (1.4 %), and the widest one 142 
in SOD2 (6.3 %). Altogether, eight different ST were obtained by combining the five MLST 143 
loci in P. boydii isolates from 14 patients, while 32 distinct ST were found in the 144 
S. apiospermum isolates from 34 patients (Table 1 and 2). Twenty-seven out of 34 patients 145 
(79.4 %) with S. apiospermum were colonized by one or two individual ST. The ST #S1, #S6 146 
and #S14 were shared by two patients, and the sequence type #S31 was found in three 147 
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individual ST (#S33 to #S35). In contrast to the high genetic diversity of S. apiospermum 149 
isolates, only five out of 14 patients harbouring P. boydii had a unique ST. The ST #P1 was 150 
identified in four, #P7 in three and #P3 in two patients. The type strain CBS 101.22T had a ST 151 
distinct from the other P. boydii isolates (#P9), but the ST of CBS 418.73 (#P6) was identified 152 
also in patient 10. Interestingly, in this patient two different ST (#P1 and #P6) were observed 153 
over a nine year period. In five other patients (5, 13, 16, 35 and 38) a unique ST was found in 154 
consecutive P. boydii isolates from a period of up to ten years (Table 1). In patients colonized 155 
by S. apiospermum it was only possible to compare isolates from a period of up to three years. 156 
Twelve patients had a unique ST. Only in patients 34 and 28 two and three different ST were 157 
found, respectively (Table 2).  158 
Discussion 159 
While the life expectancy of patients with CF changed dramatically within the last decade 160 
(25), also the spectrum of microorganisms, including fungi, colonizing the respiratory tract 161 
became more diverse (7). Therefore, to interpret the clinical relevance of colonizing fungi like 162 
Scedosporium, reproducible methods for genotyping are required. The MLST scheme 163 
developed including five loci turned out to be highly reproducible and effective for 164 
genotyping of P. boydii and S. apiospermum sensu strictu. Again the results confirm the 165 
separation of the two species as proposed by Gilgado et al. (23). Primers for the locus 166 
elongation factor 1α (EF1α) which are recommended for molecular typing of S. auranticaum 167 
and S. prolificans (17, 24) turned out to be ineffective in P. boydii and S. apiospermum. Due 168 
to the high discriminatory power of the presented MLST scheme it might be unnecessary to 169 
study this gene locus. 170 
The present study confirms the high genetic diversity within the species analysed as described 171 
before by a number of different methods (3, 10, 26). The distinction within S. apiospermum 172 
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comparable collective of CF patients from France, where P. boydii is more frequently found 174 
as S. apiospermum and therefore possibly a question of strains studied (10). Nevertheless, 175 
nearly all patients studied were colonized by individual strains, five of which harboured two 176 
or more of the P. boydii complex and S. prolificans (data not shown). Mixed colonization 177 
with different ST was apparently stable since the ST was detected in sequential samples 178 
obtained over a time span of up to nine years. Our results confirm a previous study based on 179 
random amplification of polymorphic DNA (RAPD) (3), which found a high genetic diversity 180 
in S. apiospermum colonizing CF patients and documented the persistence of strains over a 181 
period of thirteen months. These authors found that different genotypes from the same patient 182 
were usually closely related. In contrast, our MLST data indicate that genotypes within the 183 
same patient can be clearly distinct and fungi can permanently colonize the respiratory tract. It 184 
is open for discussion whether an antifungal therapy could modify the colonization pattern. 185 
Distinct phenotypes regarding the resistance pattern of the identical species can colonize the 186 
same patient (26). The aim of longitudinal studies should be to correlate the MLST data with 187 
clinical data, including the resistance pattern of isolates as well as risk factors like diabetes 188 
mellitus, cortisone and antifungal treatment. A substantial progress would be to analyse the in 189 
vitro and in vivo resistance on a molecular level. 190 
Considering the limited number of isolates, there was no striking geographic clustering of 191 
genotypes. Nevertheless, three patients with the same genotype of S. apiospermum (#S31) 192 
were found in Lower Saxony, and two other patients were harbouring an identical ST of 193 
P. boydii (#P1) in Hamburg. These patients were treated at the same CF centre. Therefore, 194 
although to our knowledge they have never met at the ambulatory, a transfer from one patient 195 
to another or an exposure to the same source of fungi cannot be excluded completely. To gain 196 
new insights on the routes of infection, Scedosporium species have to be identified in the 197 
surroundings of our patients. Our MLST scheme will allow an informative comparison of 198 
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patients from European countries varies. While in a set of clinical and environmental strains 200 
from Austria, Germany and the Netherlands S. apiospermum was the most prevalent one, 201 
followed by P. boydii (27), in Northern Spain and France P. boydii represents the most 202 
prevalent species, followed by S. apiospermum (10, 26). It would be highly informative to 203 
analyse European isolates from different countries with a unique molecular method. The 204 
MLST scheme presented here will be a promising tool for further epidemiological studies on 205 
fungi belonging to the P. boydii complex in Europe and worldwide.  206 
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Table 1 299 
List of P. boydii isolates showing the allele types of ITS and the five MLST loci and sequence 300 
types (ST). 301 
Table 2 302 
List of S. apiospermum isolates showing the allele types of ITS and the five MLST loci and 303 
sequence types (ST).  304 
Table 3 305 
Primer oligonucleotides and annealing temperature for ITS and the MLST analysis.  306 
Table 4 307 




Table 1  





Sex CFTR genotype 





Source RKI no. ITS   ACT CAL RPB2 BT2 SOD2 ST 
6 30 n.a. unknown O (NW) 2001 /07 Sputum 01-0715.01 P2 P1 P1 P1 P1 P1 #P1 
47 26 f delF508/delF508 M (NW) 2010 /09 n.d. 10-0570.01 P2   P1 P1 P1 P1 P1 #P1 
    M (NW) 2010 /09* Sputum 10-0616.01 P2 P1 P1 P1 P1 P1 #P1 
    M (NW) 2010 /09* Sputum 10-0616.02 P2   P1 P1 P1 P1 P1 #P1 
38 4 m delF508/- P (HH) 2010 /01* Throat swab 10-0143.01 P2 P1 P1 P1 P1 P1 #P1 
    P (HH) 2010 /01* Throat swab 10-0143.02 P2 P1 P1 P1 P1 P1 #P1 
    P (HH) 2010 /01* Throat swab 10-0144.01 P2 P1 P1 P1 P1 P1 #P1 
    P (HH) 2010 /05~ Sputum 10-0343.01 P2 P1 P1 P1 P1 P1 #P1 
    P (HH) 2010 /05~ Sputum 10-0344.01 P2 P1 P1 P1 P1 P1 #P1 
    P (HH) 2010 /05~ Sputum 10-0345.01 P2 P1 P1 P1 P1 P1 #P1 
37 16 f delF508/- P (HH) 2010 /01* Sputum 10-0135.01 P2   P1 P1 P1 P1 P1 #P1 
    P (HH) 2010 /01* Sputum 10-0136.01 P2 P1 P1 P1 P1 P1 #P1 
    P (HH) 2010 /02~ Sputum 10-0137.01 P2 P1 P1 P1 P1 P1 #P1 
    P (HH) 2010 /02~ Sputum 10-0138.01 P2 P1 P1 P1 P1 P1 #P1 
    P (HH) 2010 /03 Throat swab 10-0140.01 P2   P1 P1 P1 P1 P1 #P1 
10 15 m delF508/delF508 K (BY) 2001 /12 Sputum 02-0167.01 P2 P1 P1 P1 P1 P1 #P1 
    K (BY) 2002 /01 Sputum 02-0188.01 P1 P2 P3 P3 P3 P5 #P6 
    K (BY) 2002 /02 n.d. 02-0363.01 P2 P1 P1 P1 P1 P1 #P1 





Sex CFTR genotype 





Source RKI no. ITS   ACT CAL RPB2 BT2 SOD2 ST 
    K (BY) 2009 /07 Sputum 09-0504.01 P2 P1 P1 P1 P1 P1 #P1 
5 36 f delF508/delF508 K (BY) 2001 /07* Sputum 01-0710.01 P1   P1 P1 P1 P1 P2 #P2 
    K (BY) 2001 /07* Sputum 01-0711.01 P1 P1 P1 P1 P1 P2 #P2 
    K (BY) 2001 /08 Sputum 01-0719.01 P1 P1 P1 P1 P1 P2 #P2 
    K (BY) 2001 /09 Sputum 01-0830.01 P1 P1 P1 P1 P1 P2 #P2 
    K (BY) 2009 /12 Sputum 09-0822.01 P1 P1 P1 P1 P1 P2 #P2 
    K (BY) 2010 /02 Sputum 10-0165.01 P1   P1 P1 P1 P1 P2 #P2 
35 20 m delF508/delF508 F (LS) 2010 /01 Sputum 10-0049.01 P3 P1 P2 P2 P2 P3 #P3 
    F (LS) 2010 /04 Sputum 10-0254.01 P3 P1 P2 P2 P2 P3 #P3 
    F (LS) 2010 /09 Sputum 10-0594.01 P3 P1 P2 P2 P2 P3 #P3 
13 14 m delF508/delF508 F (LS) 2007 /07 n.d. 07-0385.01 P3   P1 P2 P2 P2 P3 #P3 
    F (LS) 2009 /03 Sputum 09-0257.01 P3 P1 P2 P2 P2 P3 #P3 
    F (LS) 2009 /07 Sputum 09-0563.01 P3 P1 P2 P2 P2 P3 #P3 
    F (LS) 2009 /08 Sputum 09-0573.01 P3 P1 P2 P2 P2 P3 #P3 
    F (LS) 2009 /10 Sputum 09-0730.01 P3 P1 P2 P2 P2 P3 #P3 
    F (LS) 2009 /11 Palatine tonsil swab 09-0768.01 P3 P1 P2 P2 P2 P3 #P3 
    F (LS) 2010 /02 Sputum 10-0180.01 P3 P1 P2 P2 P2 P3 #P3 
    F (LS) 2010 /03 Sputum 10-0238.01 P3   P1 P2 P2 P2 P3 #P3 
1 26 m c.1007T>A/- B (BE) 1995 /08 Sputum 95-2499.01 P1 P1 P2 P2 P2 P4 #P4 
2 16 f delF508/R553X N (BB) 1998 /11 Sputum 98-0503.01 P1   P1 P2 P4 P2 P4 #P5 
36 19 f delF508/delF508 F (LS) 2010 /01 Sputum 10-0129.01 P1 P2 P3 P3 P4 P5 #P7 
    F (LS) 2010 /04* Sputum 10-0314.01 P1 P2 P3 P3 P4 P5 #P7 




Sex CFTR genotype 





Source RKI no. ITS   ACT CAL RPB2 BT2 SOD2 ST 
23 41 m delF508/delF508 K (BY) 2009 /03 Sputum 09-0355.01 P1   P2 P3 P3 P4 P5 #P7 
20 16 f unknown B (BE) 2009 /01 Throat swab 09-0038.01 P1 P2 P3 P3 P4 P5 #P7 
    B (BE) 2009 /06 Sputum 09-0443.01 P1 P2 P3 P3 P4 P5 #P7 
46 18 f delF508/c.1521-1523delCTT Q (RP) 2010 /07* Sputum 10-0455.01 P1   P3 P4 P4 P5 P6 #P8 
    Q (RP) 2010 /07* Sputum 10-0455.02 P1   P3 P4 P4 P5 P6 #P8 
CBS 418.73 n.d. n.d. none n.d. n.d. Soil (Tadzhikistan) - P1 P2 P3 P3 P3 P5 #P6 
CBS 101.22T n.d. n.d. none n.d. n.d. Mycetoma (USA) - P1   P4 P5 P2 P2 P4 #P9 
 
 
n.d. – no data; § - age at the date of first isolation of Scedosporium ssp.; m – male; f – female; CFTR - Cystic Fibrosis Transmembrane conductance 
Regulator; *,~ - multiple isolates from the same sample; BY – Bavaria; BE – Berlin; BB - Brandenburg; HH - Hamburg; LS – Lower Saxony; NW 









Sex CFTR genotype 





Source RKI no. ITS   ACT CAL RPB2 BT2 SOD2 ST 
29 21 m unknown F (LS) 2009 /08 Sputum 09-0593.01 S1   S1 S1 S1 S1 S1 #S1 
39 28 m delF508/delF508 A (BE) 2010 /02 Sputum 10-0177.01 S1 S1 S1 S1 S1 S1 #S1 
32 21 f unknown F (LS) 2009 /11 Sputum 09-0800.01 S1   S1 S1 S1 S1 S9 #S2 
9 12 f unknown B (BE) 2002 /01 Sputum 02-0098.01 S1   S1 S1 S1 S3 S1 #S3 
16 19 f unknown B (BE) 2008 /12 n.d. 08-0617.01 S1 S1 S1 S1 S5 S1 #S4 
30 11 f delF508/R553X F (LS) 2009 /09 Sputum 09-0652.01 S1   S1 S1 S3 S1 S4 #S5 
    F (LS) 2009 /10 Sputum 09-0752.01 S1 S1 S1 S3 S1 S4 #S5 
    F (LS) 2009 /12 Sputum 10-0038.01 S1 S1 S1 S3 S1 S4 #S5 
    F (LS) 2010 /04* Sputum 10-0316.01 S1 S1 S1 S3 S1 S4 #S5 
    F (LS) 2010 /04* Sputum 10-0317.01 S1 S1 S1 S3 S1 S4 #S5 
34 13 m delF508/delF508 F (LS) 2009 /12 Tracheal secretion 10-0037.01 S1   S1 S2 S1 S1 S3 #S6 
    F (LS) 2010 /02 Sputum 10-0179.01 S1 S1 S2 S1 S1 S3 #S6 
    F (LS) 2010 /06* Sputum 10-0416.01 S1 S2 S4 S1 S1 S1 #S21 
    F (LS) 2010 /06* Sputum 10-0417.01 S1 S1 S2 S1 S1 S3 #S6 
    F (LS) 2010 /09 Sputum 10-0595.01 S1   S1 S2 S1 S1 S3 #S6 
45 20 f delF508/G542X F (LS) 2010 /06 Sputum 10-0418.01 S1 S1 S2 S1 S1 S3 #S6 
28 25 m delF508/delF508 F (LS) 2009 /07 Sputum 09-0564.01 S1   S1 S2 S1 S1 S9 #S7 
    F (LS) 2009 /11 Sputum 09-0751.01 S1 S2 S1 S1 S1 S10 #S14 





Sex CFTR genotype 





Source RKI no. ITS   ACT CAL RPB2 BT2 SOD2 ST 
    F (LS) 2010 /08 Sputum 10-0593.01 S1   S2 S1 S1 S1 S10 #S14 
44 14 f unknown G (BW) 2010 /04 Sputum 10-0257.01 S1 S1 S2 S1 S4 S3 #S8 
11 18 f delF508/1525-1G>A I (BW) 2003 /12 Sputum 03-0533.01 S3   S1 S3 S1 S6 S1 #S9 
3 12 f unknown C (BY) 2001 /03 Sputum 01-0521.01 S1 S1 S4 S1 S7 S9 #S10 
14 33 m unknown I (BW) 2007 /11 Sputum 07-0591.01 S1   S1 S4 S1 S1 S8 #S11 
    I (BW) 2008 /11 Sputum 09-0021.01 S1   S1 S4 S1 S1 S8 #S11 
25 22 f delF508/1717A B (BE) 2009 /06* Sputum 09-0441.01 S2 S1 S4 S2 S5 S8 #S12 
    B (BE) 2009 /06* Sputum 09-0442.01 S2 S1 S4 S2 S5 S8 #S12 
    A (BE) 2010 /09 Sputum 10-0577.01 S2 S1 S4 S2 S5 S8 #S12 
26 16 f unknown L (BY) 2009 /06 Sputum 09-0450.01 S1   S2 S1 S1 S1 S1 #S13 
40 19 m delF508/delF508 A (BE) 2010 /03 Sputum 10-0208.01 S1 S2 S1 S1 S1 S10 #S14 
48 19 m delF508/delF508 F (LS) 2010 /09 Sputum 10-0637.01 S1   S2 S1 S1 S1 S11 #S15 
8 23 f unknown B (BE) 2002 /01 n.d. 02-0042.01 S1 S2 S1 S1 S3 S1 #S16 
31 22 f unknown F (LS) 2009 /09 Sputum 09-0653.01 S1   S2 S1 S2 S1 S5 #S17 
    F (LS) 2009 /09 Sputum 09-0654.01 S1   S2 S1 S2 S1 S5 #S17 
7 29 f unknown K (BY) 2001 /03 Sputum 01-0718.01 S1 S2 S2 S1 S1 S3 #S18 
    K (BY) 2001 /11 Sputum 01-0988.01 S1 S2 S2 S1 S1 S3 #S18 
24 26 m unknown B (BE) 2009 /06 n.d. 09-0422.01 S1   S2 S2 S1 S7 S8 #S19 
    A (BE) 2009 /09 Tracheal secretion 09-0706.01 S1   S2 S2 S1 S7 S8 #S19 
21 6 m delF508/delF508  C (BY) 2009 /02 Throat swab 09-0141.01 S3 S2 S3 S1 S6 S1 #S20 
19 10 f R553X/R553X K (BY) 2008 /10 Sputum 08-0633.01 S1   S3 S1 S1 S1 S1 #S22 




Sex CFTR genotype 





Source RKI no. ITS   ACT CAL RPB2 BT2 SOD2 ST 
    K (BY) 2009 /08 Sputum 09-0539.01 S1 S3 S1 S1 S1 S1 #S22 
    K (BY) 2009 /12 Sputum 09-0823.01 S1   S3 S1 S1 S1 S1 #S22 
33 15 m delF508/R533X H (BW) 2009 /11 Sputum 09-0821.01 S1 S3 S1 S1 S6 S8 #S24 
43 15 f unknown C (BY) 2010 /04 Throat swab 10-0256.01 S1   S3 S1 S2 S6 S1 #S25 
42 36 m delF508/delF508 F (LS) 2010 /03 Sputum 10-0253.01 S1 S3 S2 S4 S1 S7 #S26 
    F (LS) 2010 /06 Sputum 10-0471.01 S1 S3 S2 S4 S1 S7 #S26 
4 19 f unknown D (BW) 2001 /05 Tracheal secretion 01-0602.01 S2   S3 S3 S2 S2 S5 #S27 
    D (BW) 2001 /05 BAL 01-0603.01 S2   S3 S3 S2 S2 S5 #S27 
17 11 m delF508/delF508 B (BE) 2008 /12 n.d. 08-0619.01 S1 S3 S3 S3 S1 S1 #S28 
18 14 f delF508/2146delT B (BE) 2008 /12 n.d. 08-0620.01 S1   S3 S4 S1 S2 S8 #S29 
27 22 f delF508/delF508 E (BW) 2009 /06* Sputum 09-0475.01 S2 S4 S1 S2 S6 S6 #S30 
    E (BW) 2009 /06* Sputum 09-0475.02 S2 S4 S1 S2 S6 S6 #S30 
    E (BW) 2010 /03 Sputum 10-0222.02 S2 S4 S1 S2 S6 S6 #S30 
41 10 f delF508/delF508 F (LS) 2010 /03 Palatine tonsil swab 10-0252.01 S2   S4 S3 S2 S2 S2 #S31 
    F (LS) 2010 /09 Throat swab 10-0638.01 S2   S4 S3 S2 S2 S2 #S31 
12 17 f delF508/delF508 F (LS) 2007 /04 n.d. 07-0291.01 S2 S4 S3 S2 S2 S2 #S31 
    F (LS) 2008 /01 BAL 08-0042.01 S2 S4 S3 S2 S2 S2 #S31 
    F (LS) 2008 /04 Ethmoid 08-0196.01 S2 S4 S3 S2 S2 S2 #S31 
    F (LS) 2008 /04 BAL 08-0197.01 S2 S4 S3 S2 S2 S2 #S31 
22 33 m unknown F (LS) 2009 /02 Sputum 09-0169.01 S2   S4 S3 S2 S2 S2 #S31 
    F (LS) 2009 /07 Sputum 09-0561.01 S2 S4 S3 S2 S2 S2 #S31 




Sex CFTR genotype 





Source RKI no. ITS   ACT CAL RPB2 BT2 SOD2 ST 
    F (LS) 2009 /11 BAL 09-0770.01 S2 S4 S3 S2 S2 S2 #S31 
    F (LS) 2009 /11 Tissue 09-0789.01 S2   S4 S3 S2 S2 S2 #S31 
15 36 f R347P/1078delT B (BE) 2008 /03 Sputum 08-0118.01 S4 S5 S2 S2 S1 S1 #S32 
    B (BE) 2008 /12 n.d. 08-0618.01 S4 S5 S2 S2 S1 S1 #S32 
    A (BE) 2010 /07 Sputum 10-0054.01 S4 S5 S2 S2 S1 S1 #S32 
CBS 100395 56 m none none 1993 BAL (HTX; Gemany) - S1   S2 S1 S1 S1 S3 #S33 
CBS 100392 63 m none none 1993 Biopsy leg (Hungary) - S1 S3 S1 S5 S1 S12 #S34 
CBS 117407T n.d. n.d. none none n.d. Keratitis (Brazil) - S2   S3 S1 S2 S8 S8 #S35 
 
n.d. – no data; § - age at the date of first isolation of Scedosporium ssp.; m – male; f – female; CFTR - Cystic Fibrosis Transmembrane conductance 
Regulator; *,~ - multiple isolates from the same sample; BW - Baden-Württemberg, BY – Bavaria; BE – Berlin; LS – Lower Saxony; CBS – 















ITS ~ 650 
ITS5 - GGAAGTAAAAGTCGTAACAAGG 
ITS4 - TCCTCCGCTTATTGATATGC 
55 (15) 
ACT ~ 1,000 
ACT-1 - TGGGACGATATGGAIAAIATCTTGCA 
ACT-4R - TCITCGTATTCTTGCTTIGAICTCCACAT 
57 (18) 
CAL ~ 650 
CAL-FW - GACTATTCACTAACAACGCTGTG 
CAL-RW - GTCTAGTATAATCAAATCGTTAGAG 
55 this study 
RPB2* ~ 1,300 
RPB2-5F - GAYGAYMGWGATCAYTTYGG 
RPB2-7R - CCCATRGCTTGYTTRCCCAT 
55 (19) 
BT2 ~ 650 
BT2a - GGTAACCAAATCGGTGCTGCTTTC 
BT2b - ACCCTCAGTGTAGTGACCCTTGGC 
58 (16) 
SOD2 ~ 550 
SOD2-F3 - TCACCACGATAAACACCACC 
SOD2-R3 - CGTCGATACCCAAGAGAGGA 
52 
Unpublished, 
from W. Meyer 
R: G or A; W: A or T; Y: C or T; M: A or C 
*For RPB2 sequencing additional primer RPB2-6F 5’-TGGGGKWTGGTYCCTGC-3’, RPB2-6R 5’-
GCAGGCCARACCAWMCCCCA-3’ was used. 
Amplification/sequencing failed for: EF1α (EF-1 ATG GGT AAG GAR GAC AAG AC and EF-2 GGA RGT ACC AGT SAT 
CAT G; EF-1H ATG GGT AAG GAR GAC AAG AC and EF-2T GGA AGT ACC AGT GAT CAT GTT (21), EF1-7(28) F CAT 
CGA GAA GTT CGA GAA GG and EF1-9(86) R TAC TTG AAG GAA CCC TTA CC (22) 
Table(s)
Table 4 
Variability between the gene loci. 
Locus 
Sequence 
start [5’ - 3‘] 
Sequence 
end [5’ - 3‘] 
Size 
[bp] 
P. boydii  S. apiospermum  
Alleles [n] Polymorphism [n] [%] Alleles [n] Polymorphism [n] [%] 
ACT ATCAAC GCGAAA 782 4 18 2.3 5 11 1.4 
CAL TTAAAG TATCCC 579 5 9 1.6 4 8 1.4 
RPB2 TAAGCT TCCCAA 1,092 4 19 1.7 5 17 1.6 
BT2 GACGAC CAGTCC 526 5 24 4.6 8 31 5.9 
SOD2 TCTCCA GCGCGA 396 6 58 14.6 12 25 6.3 
Sum/Total   3,375  128 3.8  92 2.7 
 
Table(s)
